Arbutus Biopharma Q2 2026: $178.4M Moderna Settlement Drives Profit, Pipeline Advances
ABUS sits 36% above its 52-week low of $3.31.
Summary
Arbutus Biopharma's Q2 2026 results show a $5.1M net loss for the quarter but a $164.6M profit for the first half, fueled by the Moderna settlement. The company has a strong cash position, advancing pipeline, and new patent lawsuits against Pfizer/BioNTech.
Key Events · Earnings and Guidance · ABUS
-
Moderna Settlement Revenue Recognized
Arbutus recognized $178.4 million in license revenue from the Moderna settlement in the first half of 2026, driving a six-month net income of $164.6 million. The cash was received on July 8, 2026.
-
Strong Cash Position
Cash, equivalents, and marketable securities totaled $92.6 million at June 30, 2026, with an additional $178.4 million received post-quarter. Management believes this funds operations for at least 12 months.
-
Pipeline Progress
Imdusiran received FDA Fast Track designation, and the company reached alignment with the FDA on a Phase 2b clinical trial design. AB-101 Phase 1a/1b data showed high receptor occupancy and HBsAg declines.
-
New Pfizer/BioNTech Lawsuits
In July 2026, Arbutus and Genevant filed three international patent infringement lawsuits against Pfizer/BioNTech in Canada and the Unified Patent Court, seeking damages and injunctions.
Analysis · ABUS · Life Sciences
Arbutus Biopharma reported a net loss of $5.1 million for Q2 2026, but the six-month period swung to a $164.6 million profit thanks to the recognition of $178.4 million in revenue from the Moderna patent settlement. The company ended June with $92.6 million in cash and investments, and received the $178.4 million settlement payment on July 8, 2026, extending its cash runway well beyond 12 months. Operating expenses fell sharply as the company streamlined operations, while the pipeline advanced with FDA Fast Track designation for imdusiran and alignment on a Phase 2b trial design. The company also filed new international patent lawsuits against Pfizer/BioNTech in July 2026, signaling continued aggressive IP enforcement.
At the time of this filing, ABUS was trading at $4.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $922.5M. The 52-week trading range was $3.31 to $5.38. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.